Duvelisib (Synonyms: IPI-145; INK1197)

Name: Duvelisib
Brand: MedChemExpress
SKU: HY-17044
Rating: 5.0 (17 reviews)

Cat. No.: HY-17044 Purity: 99.88%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC₅₀ of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively.

For research use only. We do not sell to patients.

CAS No. : 1201438-56-3

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 17 publication(s) in Google Scholar

Other Forms of Duvelisib:

Duvelisib (R enantiomer) In-stock
Duvelisib (Standard) In-stock

17 Publications Citing Use of MCE Duvelisib

Cell Proliferation/Viability Assay

Bio/Physico-chemical Assay

: Duvelisib purchased from MedChemExpress. Usage Cited in: Blood Adv. 2025 Jul 2:bloodadvances.2024015322. [Abstract]; A bar plot reported the percent viability assessed by propidium iodide (PI) incorporation in TLBR2 cells cultured alone or in the presence of MS-5 and treated with navitoclax (1-2 µM) for 72 hours.

: Duvelisib purchased from MedChemExpress. Usage Cited in: Blood Adv. 2025 Jul 2:bloodadvances.2024015322. [Abstract]; Heat map reported cell viability of the ALK+ 36 ALCL SUPM2 cell line treated for 72 hours with the indicated drugs (x-axis) and concentrations (y-axis).

: Duvelisib purchased from MedChemExpress. Usage Cited in: RSC Adv. 2025 Dec 18;15(59):50944-50962. [Abstract]; RMSD plots showed structural dynamics upon binding with the inhibitors during a 250 ns MD simulation ligand, for standard mutant IDH1 inhibitors, olutasidenib (black) and α-mangostin (red), screened inhibitors, atogepant (green), dacomitinib (blue), duvelisib (yellow), idelalisib (brown), and vandetanib (turquoise), and an inactive reference compound, temozolomide (orange).

: Duvelisib purchased from MedChemExpress. Usage Cited in: RSC Adv. 2025 Dec 18;15(59):50944-50962. [Abstract]; Hbond analysis was performed during the 250 ns MD simulation for the standard mutant IDH1 inhibitor duvelisib. Each horizontal line on the y-axis represented the number of hydrogen bonds formed simultaneously, with its duration shown along the time on the (x) axis. A higher and denser clustering of lines suggested stronger and more stable interactions throughout the simulation period.

: Duvelisib purchased from MedChemExpress. Usage Cited in: Oncoimmunology. 2022 Oct 11;11(1):2134536.; Immunoblots showed that Duvelisib (24 h) suppressed the expression of Pon2, decreased the phosphorylated IκB kinase (IKK) complex, and activated the NF-κB p65 in Rhoa G17V-expressing CD4+ T cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PI3K Isoform Specific Products:

View All Isoforms

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

Biological Activity
Purity & Documentation
References
Customer Review

Description

Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC₅₀ of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively^[1]^[2].

IC₅₀ & Target^[2]

p110δ

2.5 nM (IC₅₀)

p110γ

27.4 nM (IC₅₀)

p110β

85 nM (IC₅₀)

p110α

1602 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
4T1	IC₅₀	22.88 μM Compound: Duvelisib	Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against mouse 4T1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
A549	IC₅₀	> 100 μM Compound: Duvelisib	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
B16-F10	IC₅₀	> 100 μM Compound: Duvelisib	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
DOHH-2	IC₅₀	0.2 μM Compound: 1; IPI-145	Antiproliferative activity against human DOHH-2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human DOHH-2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35831917]
HepG2	IC₅₀	> 100 μM Compound: Duvelisib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
Huh-7	IC₅₀	6.57 μM Compound: Duvelisib	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
Jurkat	IC₅₀	1.9 μM Compound: Duvelisib	Antiproliferative activity against human Jurkat cells after 3 days by CellTiter-Glo assay Antiproliferative activity against human Jurkat cells after 3 days by CellTiter-Glo assay	[PMID: 27774127]
Jurkat	IC₅₀	3.17 μM Compound: Duvelisib	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
L929	IC₅₀	> 100 μM Compound: Duvelisib	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against mouse L929 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
LOUCY	IC₅₀	0.98 μM Compound: Duvelisib	Antiproliferative activity against human Loucy cells after 3 days by CellTiter-Glo assay Antiproliferative activity against human Loucy cells after 3 days by CellTiter-Glo assay	[PMID: 27774127]
MCF7	IC₅₀	> 100 μM Compound: Duvelisib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
MDA-MB-231	IC₅₀	9.76 μM Compound: Duvelisib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
MOLM-14	IC₅₀	1.2 μM Compound: Duvelisib	Antiproliferative activity against human MOLM14 cells after 3 days by CellTiter-Glo assay Antiproliferative activity against human MOLM14 cells after 3 days by CellTiter-Glo assay	[PMID: 27774127]
MOLT-4	IC₅₀	2.3 μM Compound: Duvelisib	Antiproliferative activity against human MOLT4 cells after 3 days by CellTiter-Glo assay Antiproliferative activity against human MOLT4 cells after 3 days by CellTiter-Glo assay	[PMID: 27774127]
MV4-11	IC₅₀	4.4 μM Compound: Duvelisib	Antiproliferative activity against human MV4-11 cells after 3 days by CellTiter-Glo assay Antiproliferative activity against human MV4-11 cells after 3 days by CellTiter-Glo assay	[PMID: 27774127]
RAW264.7	IC₅₀	0.025 μM Compound: 4; IPI-145	Inhibition of PI3Kgamma in rat RAW264.7 cells assessed as reduction in C5a-stimulated AKT phosphorylation at Ser473 residue preincubated for 30 mins followed by C5a-stimulation and measured after 5 mins Inhibition of PI3Kgamma in rat RAW264.7 cells assessed as reduction in C5a-stimulated AKT phosphorylation at Ser473 residue preincubated for 30 mins followed by C5a-stimulation and measured after 5 mins	[PMID: 31033293]
RAW264.7	IC₅₀	13.2 μM Compound: Duvelisib	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
Raji	IC₅₀	0.36 nM Compound: 15	Cytotoxicity against in human Raji cells Cytotoxicity against in human Raji cells	[PMID: 30582813]
Raji	IC₅₀	2.5 nM Compound: 15	Inhibition of PI3Kdelta in human Raji cells Inhibition of PI3Kdelta in human Raji cells	[PMID: 30582813]
Raji	IC₅₀	27 nM Compound: 15	Inhibition of PI3Kgamma in human Raji cells Inhibition of PI3Kgamma in human Raji cells	[PMID: 30582813]
Ramos	IC₅₀	0.001 μM Compound: 4; IPI-145	Inhibition of PI3Kdelta in human Ramos cells assessed as reduction in antihuman IgM-stimulated AKT phosphorylation at Ser473 residue preincubated for 60 mins followed by antihuman IgM stimulation and measured after 15 mins Inhibition of PI3Kdelta in human Ramos cells assessed as reduction in antihuman IgM-stimulated AKT phosphorylation at Ser473 residue preincubated for 60 mins followed by antihuman IgM stimulation and measured after 15 mins	[PMID: 31033293]
SU-DHL-6	IC₅₀	0.39 μM Compound: 1; IPI-145	Antiproliferative activity against human SU-DHL-6 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human SU-DHL-6 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35831917]
SU-DHL-6	IC₅₀	0.4 nM Compound: 1; IPI-145	Antiproliferative activity against human SUDHL2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human SUDHL2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35831917]
SUD4	IC₅₀	0.27 μM Compound: 1; IPI-145	Antiproliferative activity against human SU-DHL-4 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human SU-DHL-4 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35831917]
Sf21	IC₅₀	0.001 μM Compound: 4; IPI-145	Inhibition of N-terminal His6-tagged recombinant full length human p110delta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay Inhibition of N-terminal His6-tagged recombinant full length human p110delta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay	[PMID: 31033293]
Sf21	IC₅₀	0.008 μM Compound: 4; IPI-145	Inhibition of N-terminal His6-tagged recombinant full length human p110beta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay Inhibition of N-terminal His6-tagged recombinant full length human p110beta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay	[PMID: 31033293]
T47D	IC₅₀	> 100 μM Compound: Duvelisib	Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human T47D cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]
THP-1	IC₅₀	14.89 μM Compound: Duvelisib	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 37011446]

In Vitro

PI3Kδ and PI3Kγ inhibition with Duvelisib (IPI-145) has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with Duvelisib inhibits both adhesion and migration of AML blasts to bone marrow stromal cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

416.86

Formula

C₂₂H₁₇ClN₆O

CAS No.

1201438-56-3

Appearance

Solid

Color

Off-white to gray

SMILES

O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)C)=CC5=C1C(Cl)=CC=C5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (239.89 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3989 mL	11.9944 mL	23.9889 mL
5 mM	0.4798 mL	2.3989 mL	4.7978 mL
10 mM	0.2399 mL	1.1994 mL	2.3989 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (11.99 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.88%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (252 KB) RP-HPLC (208 KB)

Handling Instructions (2659 KB)

References

[1]. Pillinger G, et al. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget. 2016 Jun 28;7(26):39784-39795. [Content Brief]

[2]. G?ckeritz E, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 1;137(9):2234-42. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3989 mL	11.9944 mL	23.9889 mL	59.9722 mL
	5 mM	0.4798 mL	2.3989 mL	4.7978 mL	11.9944 mL
	10 mM	0.2399 mL	1.1994 mL	2.3989 mL	5.9972 mL
	15 mM	0.1599 mL	0.7996 mL	1.5993 mL	3.9981 mL
	20 mM	0.1199 mL	0.5997 mL	1.1994 mL	2.9986 mL
	25 mM	0.0960 mL	0.4798 mL	0.9596 mL	2.3989 mL
	30 mM	0.0800 mL	0.3998 mL	0.7996 mL	1.9991 mL
	40 mM	0.0600 mL	0.2999 mL	0.5997 mL	1.4993 mL
	50 mM	0.0480 mL	0.2399 mL	0.4798 mL	1.1994 mL
	60 mM	0.0400 mL	0.1999 mL	0.3998 mL	0.9995 mL
	80 mM	0.0300 mL	0.1499 mL	0.2999 mL	0.7497 mL
	100 mM	0.0240 mL	0.1199 mL	0.2399 mL	0.5997 mL

Duvelisib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Duvelisib1201438-56-3IPI-145 INK1197IPI145IPI 145INK1197INK 1197INK-1197PI3KPhosphoinositide 3-kinaseInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Duvelisib (Synonyms: IPI-145; INK1197)

Customer Review

Other Forms of Duvelisib:

Duvelisib Related Antibodies

17 Publications Citing Use of MCE Duvelisib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PI3K Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Duvelisib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Duvelisib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report